Tech Company Financing Transactions
Palleon Pharmaceuticals Funding Round
Palleon Pharmaceuticals secured a $47.6 million Series A funding round on 10/5/2017. Backers included AbbVie Biotech Ventures, Pfizer Venture Investments and SR One Capital Management.
Transaction Overview
Company Name
Announced On
10/5/2017
Transaction Type
Venture Equity
Amount
$47,600,000
Round
Series A
Investors
Proceeds Purpose
The Series A funding will be used to establish and advance a first-in-class pipeline of drug candidates targeting Glycoimmune Checkpoints -- receptors on immune cells that normally distinguish self versus non-self but get exploited in cancer to create immunosuppression that allows tumors to thrive.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
266 Second Ave.
Waltham, MA 02451
USA
Waltham, MA 02451
USA
Phone
Website
Email Address
Overview
Palleon Pharmaceuticals is the leading biotechnology company focused on developing Glycoimmune Checkpoint inhibitors to treat cancer.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
James Broderick
Chief Medical Officer
Robert Sikorski
Chief Scientific Officer
Li Peng
Co-Founder
Carolyn Bertozzi
Co-Founder
Paul Crocker
VP - Bus. Development
Karl Normington
VP - Operations
John Hennessy
Browse more venture capital transactions:
Prev: 10/5/2017: Heatworks venture capital transaction
Next: 10/5/2017: Acer Therapeutics venture capital transaction
Share this article
About Database of VC Transactions
We do our best to record all VC transactions involving tech companies. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs